PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kellerer, C.* ; Kahnert, K.* ; Trudzinski, F.C.* ; Lutter, J. ; Berschneider, K.* ; Speicher, T.* ; Watz, H.* ; Bals, R.* ; Welte, T.* ; Vogelmeier, C.F.* ; Jörres, R.A.* ; Alter, P.*

COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort.

Respir. Med. 185:106461 (2021)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Lung function impairment in COPD is known to be related to reductions of left heart size, while short-term interventional trials with bronchodilators showed positive effects on cardiac parameters. We investigated whether COPD maintenance therapy has analogous long-term effects. METHODS: Pooled data of GOLD grade 1-4 patients from visits 1 and 3 (1.5 y apart) of the COSYCONET cohort were used. Medication was categorized as use of ICS, LABA + ICS, LABA + LAMA and triple therapy (LABA + LAMA + ICS), contrasting "always" versus "never". Echocardiographic parameters comprised left ventricular end-diastolic and -systolic diameter (LVEDD, LVESD), ejection fraction (LVEF) and left atrial diameter (LA). Associations were identified by multiple regression analysis, as well as propensity score analysis. RESULTS: Overall, 846 patients (mean age 64.5 y; 41% female) were included, 53% using ICS at both visits, 51% LABA + ICS, 56% LABA + LAMA, 40% LABA + LAMA + ICS (triple) therapy. Conversely, 30%, 32%, 28% and 42% had no ICS, LABA + ICS, LABA + LAMA or triple therapy, respectively, at both visits. Among echocardiographic measures, only LA showed statistically significant associations (increases) with medication, whereby significant effects were linked to ICS, LABA + ICS and LABA + LAMA (p < 0.05 each, "always" versus "never") and propensity score analyses underlined the role of LABA + LAMA. CONCLUSIONS: In this observational study, COPD maintenance therapy, especially LABA + LAMA, was linked to left atrial size, consistent with the results of short-term interventional trials. These findings suggest that maintenance medication for COPD does not only improve lung function and patient reported outcomes but may also have an impact on the cardiovascular system. TRIAL REGISTRATION: NCT01245933.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.415
0.000
1
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Copd ; Cardiac Size ; Ics ; Laba ; Lama ; Left Atrium ; Maintenance Medication; Ventricular-wall Stress; Lung-function; Airway-obstruction; Percent Emphysema; Pressure-volume; Heart-failure; Hyperinflation; Comorbidities; Deflation; Disease
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 0954-6111
e-ISSN 1532-3064
Zeitschrift Respiratory Medicine
Quellenangaben Band: 185, Heft: , Seiten: , Artikelnummer: 106461 Supplement: ,
Verlag Elsevier
Verlagsort 32 Jamestown Rd, London Nw1 7by, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Health Economics and Health Care Management (IGM)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-505300-001
DOI 10.1016/j.rmed.2021.106461
WOS ID WOS:000686388200001
Scopus ID 85108168822
PubMed ID 34116329
Erfassungsdatum 2021-07-19
[➜Korrektur melden]